Azitra, Inc., a Farmington, Conn.-based preclinical biotechnology company, raised $2.9m in Series A venture capital funding.
The round, which brough total funding to date to $3.75m, was led by Bios Partners.
Led by co-founder Travis Whitfill, Azitra is a preclinical biotechnology company that aims to treat skin conditions by using the skin’s own microbiome to create innovative and sustainable treatments for skin diseases ranging from eczema to staph infections. Its lead proprietary candidate, “AZT-01,” is a recombinant strain of a safe skin bacterium that secretes therapeutic proteins locally into the skin. These bacteria, when applied topically on the skin using a cream, will colonize the skin and restore the microbiome while treating the skin condition with therapeutic proteins.
The company – which had previously raised seed funding from Peter Thiel’s Breakout Labs and other non-dilutive grants – will use the funds to continue testing its platform across a variety of skin conditions such as eczema, rare genetic skin diseases and cosmetic applications.